India to Mexico: Amino Export Trade Route

To import finished pharmaceutical formulations containing Amino into Mexico, the following approvals and registrations are necessary:

• Health Registration: All pharmaceutical products must obtain a health registration from COFEPRIS before importation. This involves submitting a comprehensive dossier that includes legal, administrative, quality, preclinical, and clinical information.

• Dossier Format: The submission should follow the Common Technical Document (CTD) format, encompassing:
• Module I: Legal/Administrative Information
• Module II: Quality Information
• Module III: Preclinical Studies
• Module IV: Clinical Studies

• Timelines for Approval: COFEPRIS aims to complete the review of health registration applications within 60 days. If this period elapses without a response, the application is considered approved by default.

• Product Registration Fees: Applicants are required to provide proof of fee payment as part of the submission process. Specific fee amounts should be verified directly with COFEPRIS, as they may vary.

• GMP Inspection Requirements: Foreign manufacturers must submit a Good Manufacturing Practices (GMP) certificate or an equivalent document issued by the competent authority in the country of origin. This certificate should demonstrate compliance with international GMP standards.

Indian exporters of Amino formulations must adhere to the following quality and GMP standards to supply products to Mexico:

• GMP Certification: Manufacturing facilities must possess a GMP certificate issued by the relevant authority in India, such as the Central Drugs Standard Control Organization (CDSCO). This certificate should confirm that the facility complies with international GMP standards.

• COFEPRIS Recognition: COFEPRIS recognizes GMP certifications from regulatory agencies in countries including Brazil, Argentina, Canada, Colombia, Chile, Cuba, and the United States. While India is not explicitly listed, COFEPRIS may accept GMP certificates from Indian manufacturers if they meet international standards.

• Recent Inspections: In November 2023, Shilpa Pharma Lifesciences Limited's API manufacturing facility in Raichur, Karnataka, underwent a GMP inspection by COFEPRIS. The facility received GMP certification from COFEPRIS following the inspection.

Several regulatory changes and policy shifts have occurred in the past 18 months affecting pharmaceutical exports to Mexico:

• Abbreviated Regulatory Pathway: On July 18, 2025, COFEPRIS introduced an Abbreviated Regulatory Pathway, effective September 1, 2025. This pathway allows for expedited health registrations for medicines and medical devices already approved by internationally recognized Reference Regulatory Authorities (RRAs), including founding members of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).

• Updated GMP Guidelines: On March 20, 2025, COFEPRIS published guidelines detailing the submission of GMP documentation for active ingredients, medicines, and medical devices. These guidelines aim to streamline compliance with international standards and enhance cooperation with recognized regulatory authorities.

• Recognition of International GMP Certifications: In April 2025, COFEPRIS announced the acceptance of GMP certifications issued by regulatory agencies in Brazil, Argentina, Canada, Colombia, Chile, Cuba, and the United States. This move facilitates the recognition of international regulations and reduces administrative barriers for the pharmaceutical industry.

These developments reflect COFEPRIS's commitment to aligning with international standards and facilitating the importation of pharmaceutical products into Mexico.

The Mexican pharmaceutical market has been experiencing steady growth, driven by factors such as an aging population, increased healthcare spending, and the expansion of universal health coverage. In 2024, the market size for pharmaceutical products was estimated at approximately $20 billion USD, with a projected annual growth rate of 5% through 2025.

Amino formulations, including essential amino acids like lysine and methionine, are critical components in both human and animal nutrition. The demand for these formulations is influenced by the prevalence of conditions requiring nutritional supplementation, such as malnutrition and metabolic disorders, as well as the growth of the livestock industry.

Mexico relies significantly on imports to meet its demand for amino formulations. In 2024, imports accounted for approximately 60% of the country's amino acid supply, with domestic manufacturing fulfilling the remaining 40%. This import dependency underscores the importance of international trade partnerships in ensuring a stable supply of these essential nutrients.

Pharmaceutical products classified under HS code 30049099, which includes finished dosage forms containing amino acids, are subject to a 0% MFN import duty rate in Mexico. This exemption is part of Mexico's commitment to facilitating access to essential medicines.

In addition to import duties, imported pharmaceutical products are subject to the Value Added Tax (VAT) at a standard rate of 16%. However, certain essential medicines may qualify for a reduced VAT rate or exemption, depending on their classification and intended use.

As of March 2026, there is no Free Trade Agreement (FTA) between India and Mexico that specifically affects pharmaceutical tariffs. Consequently, Indian exporters benefit from the 0% MFN duty rate applicable to pharmaceutical products. There are no anti-dumping duties imposed on amino formulations imported from India into Mexico.

India is a significant supplier of amino formulations to Mexico, accounting for approximately 2.5% of India's total exports in this category, valued at $7.9 million USD across 77 shipments. The leading Indian exporters include:

1. 1SRI KRISHNA PHARMACEUTICALS LIMITED ($6.6M)
2. 2GRANULES INDIA LIMITED ($0.8M)
3. 3ADVANOV PHARMA PRIVATE LIMITED ($0.5M)
4. 4SBL PRIVATE LIMITED ($0.0M)

Other major countries supplying amino formulations to Mexico include the United States, China, and various European Union (EU) member states. While specific import values from these countries are not detailed here, they collectively contribute to the majority of Mexico's amino formulation imports.

India's pricing for amino formulations is generally competitive compared to other suppliers. The cost-effectiveness of Indian pharmaceutical products, combined with their adherence to international quality standards, positions India as a preferred supplier in the Mexican market. In contrast, formulations from the EU and the United States may be priced higher due to factors such as production costs and regulatory compliance expenses.

In summary, Mexico's demand for amino formulations is met through a combination of domestic production and substantial imports, with India playing a pivotal role as a key supplier. The favorable tariff structure and competitive pricing further enhance the attractiveness of Indian amino formulations in the Mexican market.

India has solidified its position as a global leader in the production of generic pharmaceuticals, supplying 20% of the world's generic drug demand as of 2024. This dominance is underpinned by a robust manufacturing infrastructure, with over 750 FDA-approved facilities and more than 2,000 WHO-GMP certified plants. Such extensive capabilities enable the efficient production of finished dosage forms containing Amino, including tablets, capsules, syrups, and injections. The country's cost-effective production methods, driven by economies of scale and a skilled workforce, further enhance its competitiveness in the global market. Additionally, India's commitment to quality is evident in its compliance with international regulatory standards, ensuring the reliability and safety of its pharmaceutical exports.

When comparing the export of Amino formulations, India offers a compelling balance of cost and quality. Indian manufacturers provide finished dosage forms at a lower price point than their European counterparts, primarily due to lower production costs and economies of scale. While Chinese manufacturers also offer competitive pricing, India's adherence to stringent international regulatory standards, such as those set by the FDA and WHO, enhances the quality perception of its products. In Mexico, Indian pharmaceutical products are well-accepted, with a track record of consistent supply and compliance with local regulatory requirements. This combination of affordability, quality, and reliability positions India favorably against competitors from China and the European Union.

The India-Mexico supply chain for Amino formulations has demonstrated high reliability. India's pharmaceutical industry boasts significant manufacturing capacity, with numerous facilities capable of producing large volumes of finished dosage forms. Advanced packaging and cold chain logistics ensure the integrity of products during transit. Over the past decade, instances of regulatory non-compliance among Indian manufacturers have decreased by 50%, reflecting a strong commitment to quality and regulatory adherence. Leading Indian pharmaceutical companies have also been expanding their production capacities to meet growing global demand, further ensuring a stable supply chain for Amino formulations to Mexico.

For Mexican buyers sourcing Amino formulations from India, the following strategies are recommended:

• Implement a Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Amino formulations.

• Negotiate Favorable Minimum Order Quantities (MOQs): While Indian manufacturers are known for flexibility, establishing clear MOQs can optimize inventory management and cost efficiency.

• Establish Clear Payment Terms: Common payment terms in India-Mexico pharmaceutical trade include letters of credit and advance payments. Clearly define these terms to maintain smooth financial transactions.

• Conduct Thorough Supplier Qualification: Evaluate potential suppliers based on their regulatory compliance history, manufacturing capabilities, and quality assurance processes to ensure product integrity.

• Stay Informed on Regulatory Changes: Regularly monitor both Indian and Mexican pharmaceutical regulations to ensure ongoing compliance and to anticipate any potential impact on the supply chain.

Cost Estimates and Timeline:

• Audit Visits to India:
• Cost: Approximately $10,000 to $15,000 USD per audit, covering travel, accommodation, and professional fees.
• Timeline: Planning and execution typically require 6 to 8 weeks, including scheduling, travel, on-site inspection, and reporting.

By adhering to this comprehensive framework, Mexican companies can effectively qualify Indian suppliers of Amino formulations, ensuring compliance with regulatory standards and the delivery of high-quality pharmaceutical products.